

Supplementary Table 1. Baseline characteristics of metformin users and non-users before propensity score matching in men

Variable	Men		p value
	Metformin users (n = 17,745)	Metformin non-users (n = 3,664)	
Age group (yr)			< 0.01
18–24	25 (0.1)	7 (0.2)	
25–34	195 (1.1)	31 (0.9)	
35–44	1,300 (7.3)	214 (5.8)	
45–54	4,184 (23.6)	663 (18.1)	
55–64	5,047 (28.4)	858 (23.4)	
65–74	3,960 (22.3)	875 (23.9)	
> 75	3,034 (17.1)	1,016 (27.7)	
Age (yr)	60 (52–71)	65 (55–76)	< 0.01
Region, metropolitan	7,716 (43.5)	1,640 (44.8)	0.156
Nationality, Korean	17,606 (99.2)	3,641 (99.4)	0.322
Household income			< 0.01
0 (lowest)	1,602 (9.0)	404 (11.0)	
1	3,013 (17.0)	531 (14.5)	
2	2,830 (16.0)	516 (14.1)	
3	2,956 (16.7)	584 (15.9)	
4	3,375 (19.0)	687 (18.8)	
5 (highest)	3,969 (22.4)	942 (25.7)	
Disability			< 0.01
No	14,907 (84.0)	2,966 (81.0)	
Physical disability	2,725 (15.4)	620 (16.9)	
Internal disability	113 (0.6)	78 (2.1)	
Lesion site of TB			< 0.01
Pulmonary	16,289 (91.8)	3,252 (88.8)	
Extra-pulmonary	1456 (8.2)	412 (11.2)	
TB history			0.02
New case	15,168 (85.5)	3,077 (84.0)	
Previously treated TB	2,577 (14.5)	587 (16.0)	
PPM hospital	12,360 (69.7)	2,702 (73.7)	< 0.01
AFB smear positivity	7,470 (42.1)	1,447 (39.5)	0.007
Culture positivity	9,705 (54.7)	1,881 (51.3)	< 0.01
Charlson Comorbidity Index			< 0.01
0	6,956 (39.2)	1,147 (31.3)	
1	7,514 (42.3)	1,492 (40.7)	
2	1,068 (6.0)	292 (8.0)	
≥ 3	2,207 (12.4)	733 (20.0)	
Comorbidity			
Transplantation	36 (0.2)	51 (1.4)	< 0.01
HIV	13 (0.1)	4 (0.1)	0.482
Cancer	594 (3.4)	201 (5.5)	< 0.01

Supplementary Table 1. Continued

Variable	Men		p value
	Metformin users (n = 17,745)	Metformin non-users (n = 3,664)	
Notification year			0.028
2011	2,420 (13.6)	575 (15.7)	
2012	2,668 (15.0)	543 (14.8)	
2013	2,494 (14.1)	525 (14.3)	
2014	2,490 (14.0)	518 (14.1)	
2015	2,533 (14.3)	494 (13.5)	
2016	2,620 (14.8)	495 (13.5)	
2017	2,520 (14.2)	514 (14.0)	
Anti-diabetic treatment			
Sulfonylurea	10,417 (58.7)	2,265 (61.8)	< 0.01
Insulin	795 (4.5)	487 (13.3)	< 0.01
Other DM medication ^{a)}	11,424 (64.4)	2,343 (64.0)	0.619
Follow-up duration (d)	238 (185–300)	234 (183–297)	< 0.01
Treatment outcome			< 0.01
Treatment success/failure	16,437 (92.6)	3,175 (86.7)	
Death due to all causes	1,308 (7.4)	489 (13.3)	
Cause of death			0.08
TB-related deaths	227 (1.3)	68 (1.9)	
Non-TB-related deaths	1,081 (6.1)	421 (11.5)	

Values are presented as number (%) or median (interquartile range).

AFB, acid-fast bacilli; DM, diabetes mellitus; HIV, human immunodeficiency virus; PPM, public-private mix; TB, tuberculosis.

^{a)}Other DM medications include dipeptidyl peptidase-4 inhibitors, glinide, thiazolidinedione, glucagon-like peptide-1, alpha-glucosidase inhibitors, and sodium-glucose cotransporter-2 inhibitors.